{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T20:05:39Z","timestamp":1786737939341,"version":"build-2736575974"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Pharmacol"],"published-print":{"date-parts":[[2020]]},"DOI":"10.4103\/ijp.ijp_174_20","type":"journal-article","created":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T08:37:35Z","timestamp":1613637455000},"page":"476","source":"Crossref","is-referenced-by-count":5,"title":["To evaluate the efficacy and safety of olopatadine 0.1% ophthalmic solution and bepotastine 1.5% ophthalmic solution in patients with vernal keratoconjunctivitis in a tertiary care hospital"],"prefix":"10.4103","volume":"52","author":[{"given":"ResuNeha","family":"Reddy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadlakonda","family":"Sruthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Sowmini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NagurSharone","family":"Grace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0253-7613.309722-1","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1517\/14656566.2015.1040760","article-title":"Advances in pharmacotherapy for allergic conjunctivitis","author":"Abelson","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"key-10.4103\/0253-7613.309722-2","doi-asserted-by":"crossref","first-page":"467","DOI":"10.4103\/0974-9233.167814","article-title":"Dry eye syndrome and allergic conjunctivitis in the pediatric population","author":"Akil","year":"2015","journal-title":"Middle East Afr J Ophthalmol","ISSN":"https:\/\/id.crossref.org\/issn\/0974-9233","issn-type":"print"},{"key":"key-10.4103\/0253-7613.309722-3","first-page":"1764","article-title":"Comparative study of the efficacy and safety of olopatadine eyedrops and sodium cromoglycate in clinical practice: A prospective study","author":"Scandashree","year":"2016","journal-title":"Int J Basic Clin Pharmacol"},{"key":"key-10.4103\/0253-7613.309722-4","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1001\/archopht.1984.01040030976029","article-title":"Diagnosis of allergic conjunctivitis","author":"Friedlaender","year":"1984","journal-title":"Arch Ophthalmol"},{"key":"key-10.4103\/0253-7613.309722-5","unstructured":"Beigelman MN. Vernal conjunctivitis. Los Angeles: By MH Friedlaender; 1950."},{"key":"key-10.4103\/0253-7613.309722-6","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1136\/bjo.2007.117812","article-title":"Prevalence of vernal keratoconjunctivitis: A rare disease?","author":"Bremond-Gignac","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"key-10.4103\/0253-7613.309722-7","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/eye.1989.63","article-title":"Limbal vernal keratoconjunctivitis: Clinical characteristics and immunoglobulin E expression compared with palpebral vernal","author":"Tuft","year":"1989","journal-title":"Eye (Lond)"},{"key":"key-10.4103\/0253-7613.309722-8","first-page":"15","article-title":"A study on the therapeutic efficacy of olopatadine hydrochloride in the management of allergic conjunctivitis","author":"Chowdhury","year":"2010","journal-title":"Med Today"},{"key":"key-10.4103\/0253-7613.309722-9","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2147\/OPTH.S3294","article-title":"Treatment of allergic conjunctivitis with olopatadine hydrochloride eye drops","author":"Uchio","year":"2008","journal-title":"Clin Ophthalmol"},{"key":"key-10.4103\/0253-7613.309722-10","doi-asserted-by":"crossref","unstructured":"McCabe CF, McCabe SE. Comparative efficacy of bepotastine besilate 1.5% ophthalmic solution versus olopatadine hydrochloride 0.2% ophthalmic solution evaluated by patient preference. Clin Ophthalmol 2012;6:1731-8.","DOI":"10.2147\/OPTH.S35431"},{"key":"key-10.4103\/0253-7613.309722-11","doi-asserted-by":"crossref","unstructured":"Kurt RA, Ucakhan-G\u00fcnd\u00fcz \u00d6, G\u00fcnd\u00fcz K. Olopatadine 0.1% and 0.2% ophthalmic solution for the management of ocular allergy. Expert Rev Ophthalmol 2010;5:287-96.","DOI":"10.1586\/eop.10.28"},{"key":"key-10.4103\/0253-7613.309722-12","unstructured":"ISTA Pharmaceuticals Bepreve Receives FDA Approval for the treatment of Ocular Itching Due to Allergies by Calisha Myers; September 9,2009."},{"key":"key-10.4103\/0253-7613.309722-13","first-page":"954","article-title":"Inhibitory effect of betotastine besilate on antigen-induced airway eosinophil infiltration and peripheral blood eosinophilia in mice","author":"Sakai","year":"1997","journal-title":"Arzneimittelforschung"},{"key":"key-10.4103\/0253-7613.309722-14","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1517\/14656566.2015.1085511","article-title":"Double-blind placebo-controlled study of bepotastine besilate in pediatric patients with perennial allergic rhinitis","author":"Okubo","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"key-10.4103\/0253-7613.309722-15","first-page":"18","article-title":"Allergic conjunctivitis: A comprehensive review of the literature","author":"La","year":"2013","journal-title":"Ital J Pediatr"},{"key":"key-10.4103\/0253-7613.309722-16","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1067\/mai.2000.111238","article-title":"Allergic and immunologic disorders of the eye.Part II: Ocular allergy","author":"Bielory","year":"2000","journal-title":"J Allergy Clin Immunol"},{"key":"key-10.4103\/0253-7613.309722-17","doi-asserted-by":"crossref","unstructured":"Vernal keratoconjunctivitis.; Buckley RJ; Int Ophthalmol Clin 1988; 28: 303-8. doi: 10.1097\/00004397-198802840-00009.","DOI":"10.1097\/00004397-198802840-00009"},{"key":"key-10.4103\/0253-7613.309722-18","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1399-3038.2007.00601.x","article-title":"Worldwide time trends for symptoms of rhinitis and conjunctivitis: Phase III of the International Study of Asthma and Allergies in Childhood","author":"Bj\u00f6rkst\u00e9n","year":"2008","journal-title":"Pediatr Allergy Immunol"},{"key":"key-10.4103\/0253-7613.309722-19","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1755-3768.2008.01347.x","article-title":"Vernal keratoconjunctivitis: A major review","author":"Kumar","year":"2009","journal-title":"Acta Ophthalmol"},{"key":"key-10.4103\/0253-7613.309722-20","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/sj.eye.6700675","article-title":"Vernal keratoconjunctivitis","author":"Bonini","year":"2004","journal-title":"Eye (Lond)"},{"key":"key-10.4103\/0253-7613.309722-21","first-page":"804870","article-title":"Increased incidence of thyroid dysfunction and autoimmunity in patients with vernal keratoconjunctivitis","author":"Stagi","year":"2014","journal-title":"Int J Endocrinol"},{"key":"key-10.4103\/0253-7613.309722-22","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/j.1399-3038.2012.01281.x","article-title":"New insights into childhood vernal keratoconjunctivitis-associated factors","author":"Tesse","year":"2012","journal-title":"Pediatr Allergy Immunol"},{"key":"key-10.4103\/0253-7613.309722-23","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1089\/jop.2005.21.400","article-title":"Efficiency of olopatadine hydrochloride 0.1% in the treatment of vernal keratoconjunctivitis and goblet cell density","author":"Corum","year":"2005","journal-title":"J Ocul Pharmacol Ther"},{"key":"key-10.4103\/0253-7613.309722-24","doi-asserted-by":"crossref","unstructured":"Hida WT, Nogueira DC, Schaefer A, Dantas PE, Dantas MC. Comparative study between 0.025% ketotifen fumarate and 0.1% olopatadine hydrochloride in the treatment of vernal keratoconjunctivitis. Arq Bras Oftalmol 2006;69:851-6.","DOI":"10.1590\/S0004-27492006000600013"},{"key":"key-10.4103\/0253-7613.309722-25","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40123-013-0019-y","article-title":"Management of vernal keratoconjunctivitis","author":"Leonardi","year":"2013","journal-title":"Ophthalmol Ther"},{"key":"key-10.4103\/0253-7613.309722-26","doi-asserted-by":"crossref","unstructured":"Dudeja L, Janakiraman A, Dudeja I, Sane K, Babu M. Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis. Indian J Ophthalmol 2019;67:1400-4.","DOI":"10.4103\/ijo.IJO_2112_18"},{"key":"key-10.4103\/0253-7613.309722-27","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0161-6420(88)33201-X","article-title":"Evaluation of topical cromolyn sodium in the treatment of vernal keratoconjunctivitis","author":"Foster","year":"1988","journal-title":"Ophthalmology"},{"key":"key-10.4103\/0253-7613.309722-28","doi-asserted-by":"crossref","unstructured":"Ackerman S, D'Ambrosio F Jr, Greiner JV, Villanueva L, Ciolino JB, Hollander DA. A multicenter evaluation of the efficacy and duration of action of alcaftadine 0.25% and olopatadine 0.2% in the conjunctival allergen challenge model. J Asthma Allergy 2013;6:43-52.","DOI":"10.2147\/JAA.S38671"},{"key":"key-10.4103\/0253-7613.309722-29","doi-asserted-by":"crossref","unstructured":"McLaurin EB, Marsico NP, Ciolino JB, Villanueva L, Williams JM, Hollander DA. Alcaftadine 0.25% versus olopatadine 0.2% in prevention of ocular itching in allergic conjunctivitis. J Allergy Clin Immunol 2014;133:AB278.","DOI":"10.1016\/j.jaci.2013.12.986"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:01:53Z","timestamp":1786734113000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.IJP_174_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020]]}},"alternative-id":["309722"],"URL":"https:\/\/doi.org\/10.4103\/ijp.ijp_174_20","relation":{},"ISSN":["0253-7613"],"issn-type":[{"value":"0253-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}